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Abstract
Background: Nocturnal enuresis (NE), or ‘bedwetting’, is a form of night-time urinary incontinence occurring in
younger children. A diagnosis of NE can be socially disruptive and psychologically stressful for a child. The most
common strategies used by parents to manage NE are waking the child during the night to use the bathroom and
limiting the child’s water intake before going to bed. Behavioural or educational therapies for NE such as
urotherapy or bladder retraining are widely accepted and considered as a mainstream treatment option for non-
neurogenic lower urinary tract dysfunction in children. Pharmacotherapy also plays an ancillary role. However, there
is no gold standard therapy or intervention to effectively manage NE.
Methods: This study aims to determine the efficacy of a herbal combination in the treatment of NE in children. The
target population for this study is 80 children aged between 6 and 14 years old (males and females) who have
primary nocturnal enuresis ≥3 per week (wet nights). The active group will receive one or two capsules per day
containing 420 mg of a proprietary blend of Urox® (Seipel Group, Brisbane, Australia) containing Cratevox™
(Crataeva nurvala L; Capparidaceae; Varuna) stem bark extract standardised for 1.5% lupeol: non-standardised
Equisetum arvense L. (Equisetaceae; Horsetail) stem extract; and, non-standardised Lindera aggregata Sims. The
primary outcome for this study is the frequency of nocturia. Secondary outcomes include safety, quality of life, and
daytime incontinence. Each participation will be involved in the trial for 32 weeks including contact with the
research team every 2 weeks for the first 8 weeks and then every 8 weeks until trial completion.
Discussion: This study examines a novel treatment for an under-researched health condition affecting many
children. Despite the availability of several therapies for NE, there is insufficient evidence to support the use of any
one intervention and as such this randomised placebo-controlled phase II trial will be an important contribution to
understanding potential new treatments for this condition.
Trial registration: Australian and New Zealand Clinical Trials Registration Number: 12618000288224.
Protocol: 23 February 2018, version 1.1.
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Background
Nocturnal enuresis (NE), or ‘bedwetting’, is a form of
night time urinary incontinence occurring in younger
children [1, 2]. More specifically, primary nocturnal en-
uresis (PNE) is defined as the involuntary discharge of
urine at night in children aged 5 years or older, who do
not have congenital or acquired defects of the central
nervous system or urinary tract and have not experi-
enced a dry period of more than 6 months [1]. NE is
classified as either monosymptomatic enuresis – enuresis
with no other lower urinary tract symptoms – or non-
monosymptomatic enuresis – enuresis with other, mainly
daytime, lower urinary tract symptoms [3]. The aetiology
of NE has been attributed to multifactorial pathophysio-
logical factors such as an altered antidiuretic hormone
profile with nocturnal polyuria, arousal failure, delayed
bladder maturation and nocturnal detrusor overactivity
[4, 5]. Common co-morbidities identified with NE are:
constipation, diabetes mellitus, developmental attention
or learning difficulties, history of recurrent urinary tract
infection (UTI) in boys, and pinworm infestation [6–8].
Current NE international prevalence rates are reported
as between 5 and 20% of children over 5 years old [4, 7,
9–11] with an incidence as high as 18.2% in an Austra-
lian school-aged children cohort. Predictive or risk fac-
tors which have been linked with NE include: age, male
gender, daytime incontinence, encopresis, social con-
cerns, delayed age of walking, positive parental history of
enuresis, and sibling history of enuresis [7, 9, 12].
A diagnosis of NE can be socially disruptive and psy-
chologically stressful for a child [2, 10]. Quality of life in-
dicators have been explored in the past to determine the
impact of NE on the life of children [9, 13, 14]. The psy-
chological impact of bladder dysfunction has been
understood to be due to the urinary symptoms them-
selves [13]. Though not a causal factor, poor school per-
formance has been reported to be higher in children
with NE [9]. A child’s interpretation of the impact of NE
on their own life also appears to vary from the parental
proxy perception of quality of life [13, 15]. Parents have
reported more often (71%) that NE had little or no im-
pact on their child’s overall quality of life, as they be-
lieved it was a developmental condition [9]. This is
supported by the fact that only half the amount of par-
ents consult a medical practitioner for this condition
[16], which suggests that the prevalence could be higher
in the community than indicated by current documented
Figures [17].
Common approaches to treatment for nocturnal enuresis
Parents often choose a combination of therapies to treat
their children with NE. The most common strategies
utilised are waking the child during the night to use the
bathroom and limiting the child’s water intake before
going to bed [18]. Behavioural or educational therapies
for NE such as urotherapy or bladder retraining are
widely accepted and considered as a mainstream treat-
ment option for non-neurogenic lower urinary tract dys-
function in children [19] with the aim to normalise
bladder emptying and storage by teaching relaxed void-
ing techniques [20]. Alarm interventions have demon-
strated moderate effectiveness in reducing NE in
approximately two thirds of children with relapse occur-
ring in half children with ceasing the treatment [21].
Transcutaneous electrical nerve stimulation (TENS) has
been examined for the treatment of NE, but has mixed
efficacy, with reported benefit in reducing NE events in
children with primary NE [22] yet no effect on children
with monosymptomatic NE [23].
Pharmacotherapy plays an ancillary role with generally
accepted pharmacological treatment options such as
desmopressin, tricyclics, or anticholinergics administered
orally [6]. Though much research has focussed on using
pharmacotherapy to treat NE, only a minority of chil-
dren actually receive such medication (9.1%) [18]. Most
children prescribed medications such as tricyclics and
desmopressin have shown improvement in reducing the
number of wet nights but have been shown to relapse
after stopping active treatment [21]. Parents have also
demonstrated low compliance (17.2%) in persisting with
medication for their children with NE [18].
The adverse effects of desmopressin are dose related
[24] with most reactions related to study medication man-
ifesting as drug hypersensitivity symptoms such as; ab-
dominal pain, headache, nausea, flushing face, and
asthma-related symptoms. An integrative approach to
treatment has been suggested in the past, given the multi-
factorial nature of NE, issues of pharmacotherapy treat-
ment refractoriness, and considerations to risk/benefit in
treatments [1]. NE has the potential to significantly impact
the psychological and social wellbeing of a child, thus al-
ternative treatment options that could be administered
with reduced adverse effects need to be explored. How-
ever, without an established standard treatment with
strong evidence effectiveness, new treatments should be
examined through placebo-controlled studies [25].
Herbal medicine for nocturnal enuresis
Given that prescription medications are cautiously used
in children and potentially have undesirable side effect
profiles, controlled clinical trials are needed to explore
complementary medicine (CM) treatments such as
herbal medicine for safety and efficacy. A Cochrane re-
view on complementary medicine and miscellaneous in-
terventions for NE was published in 2011 and
highlighted the need for larger and more rigorous trials
examining CM treatment options [10]. The review con-
cluded that although the outcome measures varied,
Schloss et al. BMC Pediatrics          (2019) 19:421 Page 2 of 14
herbal medicine seemed to perform better than imipra-
mine, both during and after treatment [10].
Herbal medicine has traditionally been used in the
treatment of symptoms for NE or urinary incontinence
[10, 11]. A historical account by Glicklich [26] chronicles
the use of herbal medicine to treat children with enur-
esis from as early as the time of the Papyrus Ebers dated
1550 B.C. In contemporary society, parents of children
with NE frequently seek herbal products from pharma-
cists to treat this condition, which has led to an in-
creased consumer demand and an associated increased
availability in pharmacies [27]. Prior and emerging clin-
ical research into the use of herbal medicine continues
to show promising outcomes and increased benefits in
reducing the relapse of symptoms in NE [28, 29]. Early
herbal medicine research for the treatment of NE has
mainly utilised herbs drawn from Traditional Chinese
medicine practices [1, 11].
UROX® and adult urinary incontinence
Urox® is an herbal formulation listed with the Australian
Therapeutic Goods Administration which contains a com-
bination of Crateva nurvala, Equisetum arvense and Lin-
dera aggregate (see Fig. 1). Urox® has been trialled
previously in a phase 2, randomised, double-blind placebo
controlled trial to reduce the symptoms of overactive
bladder (OAB) and urinary incontinence (UI) in adults
(NCT02396160) [30]. One hundred and fifty patients were
randomised to receive active or placebo capsules for 8
weeks. The primary outcome measure was urinary fre-
quency defined as the number of voluntary diurnal and /
or nocturnal micturition, self-reported via a validated
urinary diary. Secondary outcomes included the common
urinary symptoms of; urinary frequency, nocturia, urgency
and stress incontinence using participant micturition diar-
ies. Further secondary outcomes included health-related
quality of life measurements using validated question-
naires, the incontinence impact questionnaire (IIQ) and
the urinary distress inventory (UDI) [30].
The study determined that there was a reduction in all
urinary symptoms (i.e. day frequency, nocturia, urgency,
urgency incontinence, stress incontinence and total in-
continence) which reached statistical significance in all
parameters. Specifically, day frequency (n/day) reduced
from 11.53 ± .54 to 7.69 ± 2.15, statistically significant
when treatment and placebo groups were compared
(p = 0.01, 0.01–0.02). The frequency of nocturia (n/day)
was also notably reduced 4.02 ± 1.62 to 2.16 ± 1.49 after
8 weeks of treatment. The treatment vs placebo at 8
weeks was statistically and clinically significant (p = 0.03,
0.02–0.05). Urinary urgency (OR 0.02; 95%CI 0.01 to
0.03), and total incontinence (OR 0.03; 95% CI 0.01 to
0.06) were also lower (all p < 0.01) in the treatment
group. Quality of life was also noted to be significantly





The aim of the study is to determine the efficacy of the
combination of Crateva nurvala, Equisetum arvense and
Lindera aggregata in the treatment of nocturnal enuresis
in children, as assessed by frequency of nocturnal
enuresis.
Hypothesis
The combination capsule of the herbal formula ‘Urox-
Bedtime Buddy’ will reduce the frequency of nocturnal
enuresis in children aged 6 to 14 years.
Objectives
1. To improve the quality of life for children that
experience bed wetting issues by reducing the
number of times the child wets the bed a week.
2. To reduce the frequency of bed wetting a child
experiences a week which has the potential to
improve their physical, psychological and social
wellbeing.
Trial design This is a randomised, prospective, double-
blind randomised, placebo-controlled trial in which par-
ticipants, researchers and statisticians analysing the data
are blinded to which group the participants are rando-
mised. It is a parallel group or non-crossover study. The
allocation ratio is 1:1.
Methods: participants, interventions, and outcomes
Study setting
The research setting is Endeavour College of Natural
Health, 269 Wickham Street, Fortitude Valley in
Fig. 1 Summary of formulation information
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Brisbane. There is a site agreement between UTS and
Endeavour College of Natural Health, Brisbane Campus.
Eligibility criteria
The target population for this study is children aged be-
tween 6 and 14 years old (males and females) who have
primary nocturnal enuresis ≥3 per week (wet nights).
Potential participants will be excluded if they report a
diagnosis of vesicoureteral reflux, spinal dysraphism, re-
cent urotherapy, recent or current urinary tract infection
(< 1 week), active cancer with current treatment, a his-
tory of cardiac failure and a history of renal disease or
urinary retention.
Interventions
Active intervention Each capsule contains 420 mg of a
proprietary blend of Urox® (Seipel Group, Brisbane,
Australia) containing Cratevox™ (Crataeva nurvala L;
Capparidaceae; Varuna) stem bark extract standardised
for 1.5% lupeol: non-standardised Equisetum arvense L.
(Equisetaceae; Horsetail) stem extract; and, non-
standardised Lindera aggregata Sims. The TGA Ap-
proval number for the product is – AUSTL 194355.
Capsules were manufactured in a Therapeutic Goods
Administration licensed facility according to the PIC/S
Guide to Good Manufacturing Practice for Medicinal
Products, PE 009–9-15 January 2009. Capsules were
subjected to microbiological and heavy metal testing to
ensure they complied with product specifications.
The adult dose is two capsules per day taken once
daily with food. The dosage is 1 capsule in the morning
(< 40 kg) or 2 capsules in the morning (> 40 kg) for chil-
dren. The dosage regimen was determined based on sev-
eral integral methods as follows; earlier research with
Crataeva and Equisetum alone [31, 32] and more re-
cently with Schoendorfer, et al’s trial [30] with Urox
which includes the newer formulation with 3 ingredi-
ents; pharmacopeia and traditional herbal medicine text-
book dosage recommendations [33, 34] and Clark’s rule
for dosage in Children (Dose = Adult dose x Weight(kg)
/ 70) which is conservative and tends to underestimate
the required dose [35]. Urox was listed on the ARTG
6th February, 2012 and was marketed in Australia from
this date. The Bedtime Buddy is the same formula as
Urox but dosed for children and was listed with the
TGA on the 14th June, 2017 – AUSTL 290162.
Placebo The active intervention will be compared with
an identical vegetarian capsule containing colour-
matched cellulose to that of the active ingredient. Partic-
ipants will be prescribed 1 capsule in the morning (< 40
kg) or 2 capsules in the morning (> 40 kg).
Outcomes
Primary outcome Frequency of nocturnal enuresis
(Week 8)
The primary outcome for this study will measure effi-
cacy as quantified by the change from baseline in the
frequency of nocturnal enuresis at week 8. Parents are
completing a daily diary (see Fig. 3) online or via hard
copy which measures episodes of nocturia (waking wet
through the night, and / or waking wet in the morning).
The diary also captures the volume of fluid consumed in
the day, together with the compliance of taking the cap-
sule each day.
Secondary outcomes Frequency of nocturnal enuresis
(Week 4 and Week 32)
In addition to the primary outcome, change from
baseline in the frequency of nocturnal enuresis at week 4
and Week 32 will also be measured.
Safety (Week 4 and Week 8)
Secondary outcomes in Stage 1 will include on the
safety of the herbal formulation in children aged 6–14
years at Weeks 4 and 8 of the study. Data will be col-
lected from adverse reactions (type, severity, relation to
investigational product), and side effects experienced by
the participant recorded in the diary. An interim analysis
will be conducted after enrolment of 30 participants to
assess safety and continuation of the trial. Also at this
time point, a power calculation to confirm participant
numbers needed to reach statistical significance will de-
termine the total number of participants required for re-
cruitment. Safety data will be continued to be collected
throughout Stage 2.
Quality of Life (Week 4, Week and Week 32)
Further secondary outcomes will measure health-
related quality of life as measured by the Paediatric
quality-of-life questionnaire (PinQ). This is a well-
validated tool that measures the impact of NE on paedi-
atric quality of life [13]. Permission has been granted by
the author to use in this trial [36]. The PinQ will be
completed by parent and child on separate data collec-
tion forms as it has been shown that there has been in-
consistencies in proxy and child answers when filling in
the questionnaire [13]. If a child is unable to complete a
questionnaire due to lack of cognitive or communicative
development, the researcher will assist the child in de-
velopmentally appropriate language to complete the
questions. The PinQ will be completed at Baseline,
Week 4, Week 8 and Week 32. Change in Quality of Life
will be calculated based on difference from baseline at
Week 4, Week 8 and Week 32.
Daytime incontinence symptoms (Week 4, Week 8
and Week 32)
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There is a possibility that the capsule will impact
on day-time symptoms of incontinence in children as
this was demonstrated in an adult clinical trial with
the same formulation [30]. These symptoms are mea-
sured at baseline, Week 4, Week 8 (in clinic visits)
and Week 16 and Week 24 (over the phone), and in
the final visit at Week 32. Data collection will note if
there has been episodes of day-time urinary incontin-
ence, urgency, constipation, faecal incontinence. If the
parent answers yes to any of the above categories,
they average how many times per week it has oc-
curred for each symptom. Change in daytime incon-
tinence symptoms will measured as difference from
baseline at week 8 and week 32.
Total response to treatment (Week 4, Week 8 and
Week 32)
Response to treatment will also be calculated based
on the International Children’s Continence Society
guidelines [37]. Less than 50% reduction in wet nights
will be defined as ‘no response’, 50–99% reduction in
wet nights will be considered a ‘partial response’. Par-
ticipants will only be defined as having a ‘response’ if
a 100% reduction in wet nights is reported. This will
be calculated based on difference from baseline at
Weeks 4, 8 and 32.
Trial duration
Each participation will be involved in the trial for 32
weeks. The overall flow of study involvement is reported
in Fig. 2. The first 8 weeks involve the oral ingestion of
the daily capsule. The post-interventional period in-
volves weekly entry in the electronic diary recording any
ongoing episodes of nocturia for 6 months to determine
the long-term effects of the capsule on NE. There is also
2 monthly follow up phone calls to the note any new
changes to medications or additional NE treatments as
well as the daytime continence questions. A final visit to
the clinic will occur at Week 32.
Sample size
To detect a difference between the intervention group
and the control group, a calculation from a trial on des-
mopressin and oxybutynin [38] was conducted. The
power calculation used 80% power for 5% significance
based on three-month results (p = 0.001). This resulted
in the number of children required to recruit being 80
participants. This allows for a 20% attrition rate which
provides an adequate number of participants in the pri-
mary analysis.
Due to the absence of existing studies involving similar
populations and interventions, an interim sample size cal-
culation will be conducted to confirm and potentially re-
adjust the sample size as appropriate. The recalculation of
the sample size will be conducted after 30 participants
have completed the trial. The difference in the change
(from baseline) in the frequency of nocturnal enuresis at
week 8 will be calculated. This difference will then be im-
puted into the same equation used for the sample size cal-
culation applied during study design. Any readjustment
on the trial recruitment numbers will be resubmitted to
the authorising HREC committee with the interim sample
size calculation.
Recruitment
Convenience sampling techniques will be used to target
the wider social community of parents with children that
are experiencing NE. Participants will be recruited from
the general population through social media other gen-
eral recruitment channels. Several strategies will be
utilised in the recruitment including magazine advertise-
ments, web page, social media (Twitter and Facebook),
primary school newsletters, distribution of advertising
flyers placed in a variety of locations (i.e. Wellnation
Clinics reception, health food stores and holistic CM
clinics in Brisbane). Interested individuals will be di-
rected to contact the Researchers directly via phone or
email to express interest in the trial. A participant infor-
mation sheet is available to download on the trial web-
page but also is emailed to potential participants on
enquiry.
Methods: assignment of interventions
A block randomisation allocation was used based on 10
blocks of eight with an allocation of 1:1. Two extra
blocks of eight were generated for over 80 allocations.
Allocation
Sequence generation A computer-generated number
randomisation was utilised: https://www.random.org/.
No stratification was implemented due to the specified
age restriction of ages 6–14. The block randomisation
sequence generated is provided in a separate document
that is unavailable to those who enrol participants or as-
sign interventions.
Allocation concealment mechanism The allocation
concealment is through the sealed envelope system to
conceal the sequence until the interventions are
assigned. The sequence is generated and sealed by the
PI. All investigators are blinded to the allocation.
Implementation The allocation sequence will be gener-
ated by the PI (JS). Participants are screened for eligibil-
ity over the phone prior to the baseline visit. At the
baseline visit, informed consent is obtained from the
child and parent by the Trial Co-ordinator. During the
baseline visit, participants will be allocated a study
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Fig. 2 CONSORT flow chart
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number and a participant code. The study number is a
number assigned at the time of enrolment and will be in
chronological order, for e.g. 001, 002, 003. The partici-
pant will also be allocated a participant code which will
be a 2 or 3 alphabetical letter sequence which corre-
sponds with their first letter of the first, middle and last
names. The participant will be allocated to their assigned
interventional group at this stage and receive either the
Active treatment or Placebo.
Blinding (masking)
Masking: All participants, care providers/parents, all in-
vestigators, and outcomes assessors will be blinded. All
genders will be included. Unbinding of the allocation
will not occur until the analysis is complete.
Adherence
Adherence to the protocol will be measured by the num-
ber of capsules remaining at Week 8, as counted by the
researcher. No participants will be excluded based on in-
complete adherence to the protocol. Sensitivity analyses
to control for variations in adherence will be controlled
for in the analysis. Participants that seek other treatment
at any stage during their involvement in the trial will be
classified as treatment failures in the analysis.
Methods: data collection, management, and analysis
Data collection methods
The data will be collected by KR - a qualified Naturo-
path (5 years) and clinical registered nurse (RN) with
experience in clinical trials and emergency medicine in a
major tertiary hospital. She also holds a position as a Re-
search Assistant in the Clinical Trials section of the
Office of Research, Endeavour College of Natural Health
and has 10 years clinical research experience on co-
ordinating a variety of different trial designs. Data collec-
tion will occur at Weeks 0, 2, 4, 6, 8, 16, 24, and 32 by
KR. Additionally data is collected daily for 8 weeks via
parental electronic diary and then weekly for 6 months.
Screening
Once a parent, guardian or child has shown interest in
the trial via contacting the researchers, an explanation of
the clinical trial and what is involved in participation ini-
tially occurs over the phone. The researcher will email,
post, or direct the parent to the clinical trial website
where they can download a copy of the Participant In-
formation Sheet to read independently. The parent will
be encouraged to discuss the participation with the child
themselves and someone else who is able to support
them in making their decision.
A follow up phone call or email will occur several days
to a week later to verify the parent has read the informa-
tion and discussed it with their child. This is an
opportunity for further questions by the parent if
needed. During this phone call the researcher will ask
the parent if they would like their child to participate in
the trial. If the parent says yes, the researcher will use
the screening tool i.e. Participant screening procedure
form (Universal), to determine eligibility in accordance
with the defined eligibility criteria. All eligibility details
collected through the screening process and before en-
rolment will be based on parent report of existing diag-
noses rather than evaluation from an urologist or
paediatrician. If the child is eligible an appointment date
and time will be created for the participant and parent
to attend the clinical trial site.
Assessments
Outcomes will be assessed by a Case Report Form, the
Paediatric Quality-of-Life Questionnaire (PinQ), and a
Participant Diary.
Case report form The Case Report Form (CRF) will be
completed by the researcher at weeks 0, 2, 4, 6, 8, 16, 24,
and 32. The baseline data collection will include demo-
graphic data, height and weight measurement, medica-
tions including complementary and over the counter
medicines they are taking, medical history, risk factors
for NE, prior treatments for NE, continence history, fluid
intake per day. There is ongoing data collection fort-
nightly of any adverse events or concomitant medication
via phone call or clinic visit whilst taking the interven-
tion. As part of the CRF, a quality of life questionnaire
(PinQ) will be completed by both the participant and
parent/guardian at baseline, week 4, 8 and 32. The qual-
ity of life questionnaire chosen is the Paediatric Quality
of Life Questionnaire (PinQ).
Paediatric quality-of-life questionnaire (PinQ) The
impact of NE on the child’s quality of life will be measured
by the PinQ (Paediatric quality-of-life questionnaire) [13].
The PinQ is a tool used to measure urinary incontinence
Quality of Life in children with voiding dysfunction. It has
been reliably tested and validated in numerous trials since
its conception [2, 14, 39]. Permission has been granted
from the author for its use in this trial.
The PinQ will be completed by both parent and child
on separate data collection forms as it has been shown
that there has been inconsistencies in proxy and child an-
swers when filling in the questionnaire [13]. It is com-
pleted by both parent and child as prior research has
highlighted differences in reporting with proxy and self-
reporting in the same questionnaire [14]. Children as
young as 5 years old have been shown to reliably and val-
idly self-report on their health-related quality of life in
questionnaires when given the opportunity with an age-
appropriate instrument [40]. If a child is unable to
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complete a questionnaire due to lack of cognitive or com-
municative development, the researcher will assist the
child in developmentally appropriate language to complete
the questions rather than the parent influence the re-
sponse. The PinQ will be completed by both parent and
child at Baseline, Week 4, Week 8 and finally in Week 32.
Diary The daily diary for the first 8 weeks will constitute
questions covering three main areas: compliance, fluid
intake, and continence. There will be the option for the
participant to complete it as an electronic diary or as a
paper based one. This is for ease of the participant in
their own environment. In the case of the electronic
diary, the researcher will set up a widget on the parent’s
smartphone. This is a link that takes the participant dir-
ectly to their individual eDiary (which is identical to the
paper one) where the parent is required to fill it in daily.
Each participant will have an individual link which is
linked to their own data within the online survey plat-
form (Survey Gizmo). From week 9 to week 32, a weekly
diary entry instead of daily will be required to record
any weekly events of nocturia. This will be made avail-
able as an eDiary or a paper-based diary depending on
the parent/guardian.
Data management
All participant hard copy files which include; CRF, Con-
sent Form, and PinQ diaries will be kept in individual
files in plastic sleeves in a locked filing cabinet. The fil-
ing cabinet is inside the locked Clinical Trials Office,
which is located in the department of the Office of Re-
search, Level 4, Endeavour College of Natural Health.
The only people accessible to this office and filing cabi-
net are the Clinical Trial Co-ordinator (JS) and Research
Assistant (KR). Electronic forms and logs will be main-
tained as password protected files on the computers of
the researchers which are only accessible by the re-
searchers named. This includes the following docu-
ments; Participant screening procedure form (Universal),
Screening log for excluded patients and the Patient iden-
tification and enrolment log. The eDiary information is
stored on a password protected survey platform (Survey
gizmo). Data access is limited only to the research team
assigned to that project. The hard copy data files will be
stored in a locked filing cabinet in the Researcher’s office
for 7 years, then destroyed permanently. The electronic
data logs will be archived under password protected files
on local drive for 7 years from commencement date of
trial.
Statistical methods
All data will be analysed on STATA©14. Analyses will
be conducted on an intention to treat basis. Descriptive
and inferential statistics will be conducted. The
difference in change between groups will be analysed
using paired T-tests and Analysis of Variance (ANOVA).
Groups will be compared at baseline and if difference(s)
is/are ascertained, the variable(s) will be entered into the
regression model to appropriately adjust the analyses.
Sensitivity analyses will also be conducted to account for
incomplete adherence to protocol. Interim statistical
analysis for safety will occur after 30 participants have
completed. This is same timing as the re-evaluation of
the sample size calculation. All baseline, demographic,
safety and efficacy outputs data will be summarised by
treatment group. In summary tables of continuous vari-
ables, the minimum and maximum statistics the arith-
metic mean and median, the 95% confidence interval,
standard deviation, and standard error will be presented
to the same number of decimal places as the original
data. Safety outputs will be documented at the interim
analysis and end of trial in columns with number, sever-
ity, treatment group and percentage. All hypothesis test-
ing will be carried out at the 5% (2-sided) significance
level unless otherwise specified. P values will be rounded
to three decimal places. P values less than 0.001 will be
reported as < 0.001 in tables (Table 1).
Methods: participant timeline
Details for the schedule of enrolment, interventions and
assessments of this study is depicted in Fig. 3.
Week 0 (visit 1)
This is the initial baseline visit in which the parent and
child are both present. It will take approximately 1 hour.
After the researcher has outlined the trial and the poten-
tial risks and the parent and child both understand what
participation involves, informed consent is obtained. At
the baseline visit, a CRF will be firstly be completed by
researcher in consultation with the parent. The parent
and child will both independently complete the PinQ
questionnaire at separate desks. The researcher will then
explain the eDiary to the parent and help them save the
eDiary link on their smartphone and give them a paper
version if they are unable to use their phone. The next
visit will be scheduled for 4 weeks’ time (Week 4) and
will be booked at this appointment. The researcher will
contact the parent after 1–2 days of commencing the
intervention. This is over the phone or email to assess
the participant for any initial potential adverse or allergic
reaction.
Week 2 (phone call only)
The researcher will call the parent to check adherence
with the intervention and the diary as well as adverse re-
actions and changes to concomitant medications.
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Week 4 (visit 2)
The first bottle of capsules are returned at this visit to
allow the researcher to count and record remaining
intervention for confirmation of adherence. Those par-
ents who chose to complete the paper diary will also re-
turn the completed diary. Any adverse events and
concomitant medications will be noted and actioned if
required. The PinQ will be completed by the parent and
the child and the researcher will collect day-time contin-
ence data about the impact of the capsule on any day
symptoms. Another 4 weeks supply of the capsules will
be dispensed to the participant. It is anticipated this visit
will take 30min. The next visit will be scheduled for an-
other 4 weeks (Week 8).
Week 6 (phone call only)
The RA will call the parent to check adherence with the
intervention and the diary as well as adverse reactions
and changes to concomitant medications.
Week 8 (visit 3)
The child and parent will attend this final visit to deliver
the remaining bottle of capsules and diary. The RA will
count and record any remaining intervention. Any ad-
verse events and concomitant medications will be noted
and actioned if required. The PinQ will be completed by
the parent and the child and the RA will collect data
about day continence. They will be offered paper diaries
to cover the period from Week 8 to Week 32 if they do
Table 1 Details of the active and control interventions
Arms Assigned Interventions
Active Comparator: Treatment
1 capsule in the morning (≤40 kg) or
2 capsules in the morning (> 40 kg) for
8 weeks duration.
Dietary supplement: Bedtime Buddy
Active treatment- Proprietary
combination
of 420 mg of herbs.
expressed as dry herb equivalent:
Crateva nurvala 3000 mg (120mg)
Equisetum arvense 1500 mg (150mg)
Lindera Aggregata 1500 mg (150 mg)
Control Comparator: Placebo
1 capsule in the morning (≤40 kg) or
2 capsules in the morning (> 40 kg) for
8 weeks duration.
Placebo- Identical vegetarian capsule
containing colour-matched cellulose to
that of the active treatment
Fig. 3 Schedule of enrolment, interventions, and assessments
Schloss et al. BMC Pediatrics          (2019) 19:421 Page 9 of 14
not wish to use the ediary format, with a pre-paid enve-
lope to send them back to the college at the end of the
trial. The visit is anticipated to take 30min.
Weeks 16 and 24 (phone call only)
The RA will contact the parent to check for any adverse
reactions or concomitant medications, ask follow up
questions for day time continence, and check diary
compliance.
Week 32 (visit)
The parent and child will attend the college for one final
visit. The RA will finally check for any adverse reactions
and concomitant medications, ask follow up questions
for day time continence, and check diary compliance.
The parent and child will complete the PinQ for a final
time and paper diaries submitted if necessary.
Trial completion
The trial is completed for the participant and they will
receive a thank you letter for their participation. If they
have indicated on their consent form that they wish to
receive a copy of the Summary of Findings, their name
will be added to a list and they will be contacted when
the findings have been published.
Monitoring
Minimal side effects were noted from the Urox trial in
adults, with two episodes of diarrhoea, two urinary tract
infections and one episode of flatulence. There were nu-
merous side effects in the Placebo group; urinary tract
infection, diarrhoea, headache worsened asthma, wors-
ened memory, facial flushing, halitosis and worsened
arthritic pain [30]. The Safety Summary for the product
is available upon request. Safety data on side effects and
adverse events associated with the intervention will be
closely monitored and reported.
The Patient Information Sheet outlines that the parent
/ carer is able to phone the Researcher at any time if
they feel that the child is experiencing an adverse reac-
tion to the capsule. Parents are contacted via phone at
1–2 days after commencement of the capsule to deter-
mine tolerability and assess for potential adverse reac-
tions. The electronic diary also provides parents with an
opportunity to note any potential episodes of the child
feeling unwell with an option to request the researchers
contact them to further follow up. The researcher will
determine if the reaction is an adverse event (AE) or a
serious adverse event (SAE) and follow the adverse event
flow chart (see Fig. 4). All AEs are also noted in the Ad-
verse Events Log and individual participant case report
form.
A Safety Advisory Board overseeing any serious ad-
verse events (SAE) consists of three independent expert
representatives (General Practitioner, Pharmacist and
Herbal Medicine researcher and scholar). Any SAE’s will
assessed by the safety committee with 24 h to determine
if the adverse event is attributed to the interventional
agent. The ensuing action will be decided between the
Safety Advisory Board and the investigators.
In light of new information about the treatment that
may arise during the trial, the participant / parent will
be notified and it will be discussed with the parent
whether they want the child / participant to continue on
the trial. If it is decided that the participant will continue
in the study, they will be asked to sign an updated con-
sent form. Also, on receiving new information on poten-
tial harms, the researchers might consider it appropriate
to withdraw specific a participant from the clinical trial.
If this happens, the researcher will explain the reasons
and arrange for the participant’s regular health care to
continue by sending an updated letter to the child’s local
medical practitioner.
An interim analysis will be performed on the primary
endpoint when 30 participants have been randomised
and completed 8 weeks of the intervention.. The
interim-analysis will be performed by the PI, blinded for
the treatment allocation. The results of the analysis will
be discussed with the Safety Advisory Board and the re-
search team in a joint meeting. A re-calculation of the
total target sample will be applied based on the interim
analysis, with any changes to final intended sample size
reported to the ethics committees overseeing the con-
duct of the project.
Ethics and dissemination
Research ethics approval
Ethical approval to conduct the clinical trial was granted
by two Human Research Ethics Committees (HREC)
accredited by the National Health and Medical Research
Council (NHMRC): the University of Technology Sydney
HREC (NHMRC Accreditation: #EC00146; HREC project
approval: ETH17–1926) on the 15.02.2018, and then fur-
ther approved by the Endeavour College of Natural Health
HREC (NHMRC Accreditation: #EC00146; HREC project
approval: 20,180,226) on the 26.02.2018.
Protocol amendments
The protocol was amended to expand the recruitment
strategy to reach a wider target. The additional strat-
egy was to approach Brisbane primary schools via
email to advertise the trial through their social media
or newsletters to the broader school community. This
strategy was approved by both UTS and Endeavour
HREC after each individual school principal gives per-
mission and signs an approval form which is for-
warded onto the UTS HREC.
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Consent or assent
Explanation of the clinical trial and what participation
involves initially occurs over the phone at the first point
of contact when the parent of the child with NE contacts
the researchers. After the parent reads the information
sheet and discusses with the child and other family
members the implications for the child participating,
and then decide they would like to proceed with partici-
pation, they contact the researcher to determine the
child’s eligibility. The researcher will use the universal
screening tool to determine eligibility. If it is determined
the participant is eligible, the researcher books a date
and time with the parent for the baseline visit to En-
deavour College of Natural Health, 269 Wickham Street,
Fortitude Valley.
In accordance with Ethical Research Involving Chil-
dren (ERIC) Charter [41], all visits throughout the study
will occur in a room with a glass wall. At the initial visit
final queries or discussion will occur as per parental re-
quirements for details of the trial. The researcher will
ask the child what is their understanding of what it
means for them to participate in the trial to determine
their capacity in giving assent. If the child does not have
a clear understanding of the trial, the researcher will ex-
plain in language at a developmental level appropriate
for the child. A child’s refusal to participate is respected
if they have the capacity to give consent [42]. The formal
consent will be signed after the following criteria have
been met; the researcher is satisfied the parent and child
have an individual understanding of the trial and are in
Fig. 4 Adverse event flow chart
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agreement with each other without conflict in participa-
tion, and the Patient Information Sheet has been read
thoroughly by the parent and they have had the oppor-
tunity to discuss it with their family and others. Even
young children with limited cognitive capacity should be
engaged at their level in discussion about the research
and its likely outcomes [42]. A consent form for the par-
ent/guardian of the participant to sign together with the
Researcher’s signature is to be kept by the parent as
their copy of the consent.
Participants will be provided with access to a reduced
payment for car parking if they choose to drive to the
college for the visits. The car parking ticket will be vali-
dated at the College which gives the participant a re-
duced parking fee at a local car park. The participants
will also receive a fifty ($50) dollar voucher that can be
used universally at any retail outlet with an EFTPOS or
credit care facility at the final visit (Week 32) to the Col-
lege. This is a small re-imbursement for the travel costs
to the site for clinic visits.
Termination criteria
Discontinuation of the trial would only occur due to eth-
ical implications, statistical, recruitment or safety
concerns.
Ethical and Statistical implications include:
1. Adverse Events will be recorded and analysed to
confirm if they are related to the intervention being
trialled by a safety committee. If deemed more than
40% are due to the intervention, the trial will be
terminated.
Safety concerns include:
1. If data or results indicate patient safety is at risk,
the trial will be terminated.
2. If the severity or number of adverse events related
to the intervention occur [> 40%], the trial will be
terminated. An adverse event is defined as any
untoward medical occurrence that results in
hospitalisation or prolongation of hospitalisation, or
is life-threatening, or results in death or disability,
including birth defects [43].
Recruitment:
1. Insufficient accrual of participants (less than 30
people) within an 18-month time frame.
It is unlikely that this research project would be
stopped unexpectedly unless due to unforeseen circum-
stances. This trial is being monitored by UTS HREC and
Endeavour HREC. In addition, this is a TGA approved
product and is already available for retail purchase in
Australia and the United States of America. All safety
data pertaining to the product is available, however,
safety is still being monitored in this trial.
Confidentiality
Participant raw data will be collected on paper case re-
port forms with a de-identified study code. Identification
of the participant is through a single password-protected
electronic file which matches name with study code. The
Study code is only used on all data collection forms
(paper and electronic). Data will all be analysed in sum-
marised form. The electronic file which contains the
identities of the participants is stored on restricted drive
in the Endeavour College which is only accessible by the
researchers. Only de-identified data analysed in sum-
mary form will be used in presentation or publication.
Data (electronic and hard copy) will be stored for 7 years
and then permanently destroyed.
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Access to data
Access to raw data will only be available to research staff
including the trial coordinator, the PI and CI. The con-
tractual agreement states that the funding sponsor of the
trial may not have access to any data, throughout or
after the trial until all data is analysed and published.
Therefore, allowing independent research to be con-
ducted and the research staff blinded to allocation until
analysis is completed.
Ancillary and post-trial care
At the completion of the trial (after the 6 months of post
monitoring), each child will receive two bottles of the
Bedtime Buddy. Due to the blinding of the trial until
after analysis, this allows those who may be on the pla-
cebo to have access to the investigational product. If any
participant suffers psychological harm during the trial,
counselling services will be provided for the child.
Dissemination policy
Neither the complete nor any part of the results of the
study carried out under this protocol, nor any of the in-
formation provided by the sponsor for the purposes of
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performing the study, will be published or passed on to
any third party without the consent of the study sponsor.
Any investigator involved with this study is obligated to
provide the sponsor with complete test results and all
data derived from the study.
Discussion
This study examines a novel treatment for an under-
researched health condition affecting many children.
Despite the existing data supporting the plausibility of
effectiveness for this treatment in this condition [30],
the social and psychological impacts of nocturnal enur-
esis present challenges to conducting this study as
planned. The recruitment of children in clinical trials is
acknowledged as more difficult than adults for many
reasons including consent by proxy, difficulty in identify-
ing eligible participants, and higher required sample due
to lower burden of disease [44]. Recruitment can be par-
ticularly problematic for a condition such as NE given
only half of parents with children with NE consult a
medical practitioner [16]. For researchers, the role of
health professionals can be integral to identifying poten-
tial study participants for a clinical trial, and this is par-
ticularly pronounced in a paediatric study [44]. Given
the perception of NE as a developmental condition
among some parents [9], recruitment not only requires
identifying potential participants through general parent-
ing groups and social networks but also relies on parents
acknowledging the social, psychological and quality of
life impact of NE on their child.
The control method for our study may also impact on
recruitment. While the placebo-controlled trial (PCT) is
still considered the most robust method for testing new
interventions the acceptability of placebo interventions
for children is a contested issue [25]. Researchers and
policy makers have increasingly acknowledged the value
of comparative effectiveness (CE) studies in vulnerable
populations rather than PCTs but CE trials rely on an
established effective treatment for the active intervention
to be compared against [25]. Certainly, CE trials are
favoured by medical staff and parents when seeking con-
sent [45]. Despite a number of widely accepted therapies
[19] there is insufficient evidence to support such a
comparative treatment for NE in children. For this rea-
son, placebo-control is still appropriate for a non-life
threatening condition such as NE [44] yet concerns
about their child being randomized to ineffective treat-
ments may outweigh the benefits for some parents [45].
Irrespective of these challenges, the available evidence
for efficacy for the active intervention in a similar
condition coupled with the absence of strong evi-
dence for other effective treatments justifies the need
for this study.
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